Tower Research Capital (TRC)’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $106K | Buy |
5,286
+3,490
| +194% | +$70K | ﹤0.01% | 2328 |
|
|
2025
Q1 | $35.3K | Buy |
1,796
+198
| +12% | +$3.9K | ﹤0.01% | 2487 |
|
|
2024
Q4 | $36K | Buy |
1,598
+1,114
| +230% | +$25.1K | ﹤0.01% | 2775 |
|
|
2024
Q3 | $12.4K | Sell |
484
-2,759
| -85% | -$70.5K | ﹤0.01% | 3595 |
|
|
2024
Q2 | $75.8K | Buy |
3,243
+2,737
| +541% | +$64K | ﹤0.01% | 2782 |
|
|
2024
Q1 | $8.9K | Sell |
506
-4,979
| -91% | -$87.6K | ﹤0.01% | 3935 |
|
|
2023
Q4 | $75.9K | Sell |
5,485
-1,270
| -19% | -$17.6K | ﹤0.01% | 2853 |
|
|
2023
Q3 | $92.3K | Buy |
6,755
+5,373
| +389% | +$73.4K | ﹤0.01% | 2040 |
|
|
2023
Q2 | $28.2K | Sell |
1,382
-275
| -17% | -$5.61K | ﹤0.01% | 3058 |
|
|
2023
Q1 | $36K | Buy |
1,657
+698
| +73% | +$15.2K | ﹤0.01% | 2807 |
|
|
2022
Q4 | $16K | Buy |
+959
| New | +$16K | ﹤0.01% | 3337 |
|
|
2022
Q2 | – | Sell |
-208
| Closed | -$2K | – | 6166 |
|
|
2022
Q1 | $2K | Sell |
208
-1,005
| -83% | -$9.66K | ﹤0.01% | 5536 |
|
|
2021
Q4 | $11K | Buy |
1,213
+684
| +129% | +$6.2K | ﹤0.01% | 4401 |
|
|
2021
Q3 | $9K | Buy |
529
+527
| +26,350% | +$8.97K | ﹤0.01% | 4428 |
|
|
2021
Q2 | $0 | Sell |
2
-446
| -100% | – | ﹤0.01% | 5549 |
|
|
2021
Q1 | $15K | Sell |
448
-769
| -63% | -$25.7K | ﹤0.01% | 4102 |
|
|
2020
Q4 | $107K | Buy |
1,217
+36
| +3% | +$3.17K | ﹤0.01% | 2281 |
|
|
2020
Q3 | $96K | Buy |
1,181
+981
| +491% | +$79.7K | ﹤0.01% | 3171 |
|
|
2020
Q2 | $22K | Buy |
+200
| New | +$22K | ﹤0.01% | 3624 |
|